Pictet Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Pictet Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$150M	Sell	337,569 -414,856	-55%	-$193M	0.16%	160
2025 Q4	$342M	Sell	752,425 -39,033	-5%	-$16.8M	0.33%	68
2025 Q3	$311M	Buy	791,458 +55,636	+8%	+$23.3M	0.3%	83
2025 Q2	$327M	Buy	735,822 +74,635	+11%	+$34.4M	0.33%	80
2025 Q1	$322M	Buy	661,187 +141,519	+27%	+$65.9M	0.36%	76
2024 Q4	$209M	Buy	519,668 +1,665	+0.3%	+$772K	0.23%	111
2024 Q3	$240M	Sell	518,003 -45,353	-8%	-$21.8M	0.26%	99
2024 Q2	$264M	Sell	563,356 -434,938	-44%	-$189M	0.3%	82
2024 Q1	$417M	Sell	998,294 -82,752	-8%	-$35M	0.45%	51
2023 Q4	$440M	Buy	1,081,046 +22,231	+2%	+$8.21M	0.49%	47
2023 Q3	$368M	Buy	+1,058,815	New	+$370M	0.45%	54

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pictet Asset Management's VRTX Position: Q1 2026 in Review

Pictet Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 55% in Q1 2026, selling an estimated $193M and leaving 337,569 shares worth $150M. The position accounts for 0.16% of the portfolio, ranked #160.

Pictet Asset Management first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $440M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Pictet Asset Management held 337,569 shares of Vertex Pharmaceuticals worth $150M as of Q1 2026.
Pictet Asset Management sold 414,856 Vertex Pharmaceuticals shares in Q1 2026, an estimated $193M.
Vertex Pharmaceuticals made up 0.16% of Pictet Asset Management's portfolio in Q1 2026, its #160 holding.
Pictet Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Pictet Asset Management's Vertex Pharmaceuticals position peaked at $440M in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.